drugset / Trial / NCT02875067
Safety & Efficacy Study of Combination of Pembrolizumab and Lenalidomide, in Patients With Relapsed Non-Hodgkin and Hodgkin Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
This trial is to assess the safety \& efficacy of the Combination of Pembrolizumab and Lenalidomide in the management of patients with Relapsed Hodgkin Lymphoma.
Timeline
- Start
- 2016-08-29
- Primary completion
- 2017-10-02
- Completion
- 2017-10-02
Outcome
Outcome not reported
Stopped: “Merck's decision for early termination of the data”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenalidomide | Other / unclassified | 10 mg | — |
| Subject | Lenalidomide | Other / unclassified | 15 mg | — |
| Subject | Lenalidomide | Other / unclassified | 20 mg | — |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |